Overview
Proteus Digital Health built a way to record a medication being swallowed. Its ingestible sensor, wearable patch and software attracted pharmaceutical partners and helped create the first FDA-approved drug with digital ingestion tracking. The independent company nevertheless entered bankruptcy in June 2020. Otsuka bought substantially all its assets that August.[1][2]
Image 1 / 1
Proteus had encouraging pilot evidence in some settings. Abilify MyCite’s labeling still said that improved medication compliance had not been established. Commercial adoption also required patients, clinicians and payers to accept the complete workflow.[3][4]
Founding Story
Andrew Thompson, George Savage and Mark Zdeblick combined business, medicine and sensor engineering. Thompson and Savage had worked together before Proteus; Zdeblick brought expertise in miniature mechanical and electronic systems. Their founder interviews described an opportunity to bring the feedback available from medical devices into pharmaceutical treatment.[5]
The University of Illinois dates the company to 2001. Some later news accounts give 2002, while the founders’ 2012 account places an important observation about pharmaceutical information gaps at a 2003 trade show. The precise incorporation record was not recovered.[6][5][7]
In a 2009 interview, Thompson stated the technical idea plainly: “We put computers and sensors inside proven drugs.” He also described his overriding concern as ensuring “we do nothing that harms a patient.” His proposed service combined medicines with monitoring, applications and caregiver support. That was a broader commercial ambition than selling a sensor component.[8]
Timeline
- 2001: The University of Illinois records Proteus’s founding year.[6]
- 2012: FDA first permitted marketing of the ingestible sensor later used in Abilify MyCite.[1]
- 2017: Proteus-supported researchers published a hypertension and diabetes pilot. On November 13, FDA approved Abilify MyCite’s drug-device combination.[3][1]
- 2018: Otsuka announced a selective rollout through Magellan Health provider networks. An expanded collaboration included $88 million in equity and other payments to Proteus.[9][10]
- 2019–early 2020: A planned funding round failed to close. The Otsuka relationship was restructured as Proteus shifted toward oncology and infectious diseases.[11][12]
- June–August 2020: Proteus filed Chapter 11 on June 15. The bankruptcy court approved Otsuka’s asset purchase on August 19; closing followed on August 20.[2]
What They Built
The sensor activated in stomach fluid and communicated with a patch worn on the body. The patch sent information to a compatible phone; patient-authorized clinicians and caregivers could view records through a portal. Abilify MyCite incorporated the sensor into Otsuka’s aripiprazole tablet at manufacture.[13]
Proteus Discover also supported medicines co-encapsulated with a sensor pill, as shown in the study figure.[3]
The open-label, cluster-randomized pilot analyzed 109 people with uncontrolled hypertension and type 2 diabetes. It reported a larger blood-pressure reduction with the digital offering. Proteus funded the study and employed several authors. The researchers did not objectively measure adherence in the control group and explicitly could not conclude that the offering increased adherence. The study also called for longer-term evidence. These findings do not establish benefit for a different psychiatric product or population.[3]
The January 2025 FDA label retains two important limits: improved compliance or dosage modification has not been established, and delayed or missing detection makes the system unsuitable for real-time or emergency monitoring. A missing signal does not by itself establish that someone skipped medication.[4]
Market Position
Target Customers
Patients used the hardware and app, while clinicians interpreted information and pharmaceutical partners helped commercialize the system. Otsuka’s 2018 Magellan announcement described an opt-in rollout through selected regional networks to learn how the product fit daily life and clinical practice. It was not evidence of universal payer coverage.[9]
Market Size
Many patients take long-term medicines, but that broad population was not Proteus’s paying market. Its reachable market depended on a specific condition, an acceptable monitoring workflow, payer arrangements and evidence that the information changed care enough to justify its cost. Public sources reviewed here do not establish a reliable count of recurring paying users or an addressable revenue figure.
Competition
Proteus competed with simpler ways to support medication use as well as established clinical practice. In 2009, Thompson even named Walmart’s inexpensive clinics and medicines as a commercial alternative. His concern was the cost of delivering care, beyond the cost of measuring ingestion.[8]
Business Model
The Otsuka collaboration joined technology development with pharmaceutical commercialization. Its 2018 release described $88 million already paid through a mix of equity and other payments, covering a five-year development agreement. That amount should not be labeled either pure equity funding or product revenue.[10]
By January 2020, Otsuka told MedCity News it had licensed mental-health development rights, would cease future royalties and would temporarily continue purchasing sensors and wearables. Proteus pursued oncology and infectious diseases with fewer staff. The relationship had changed before the bankruptcy sale.[12]
A January 2019 company announcement named Fairview Health Services and University of Minnesota Health in a digital capecitabine program. A subsequent conference abstract described 11 participants. This documented a small clinical deployment, while leaving large-scale adoption and commercial margins unproved.[14][15]
Outcome and evolution
The financing failure preceded COVID-19. Nature Biotechnology reported in February 2020 that a late-2019 round had failed to close and employees had been furloughed. The article discussed clinical adoption difficulties, but its suggested link between a disappointing study and the investment decision remained an interpretation.[11]
Regulatory acceptance also varied by jurisdiction. Otsuka withdrew its European application for Abilify MyCite on July 17, 2020. EMA said it lacked sufficient evidence that the complete system reliably measured ingestion in the intended population. It identified usability, skin-reaction and potential repeat-dosing concerns. This was a withdrawn European application, distinct from the earlier US approval.[16]
MedCity reported a $15 million cash bid and no competing bidder by the auction deadline. Buyer counsel confirms that the completed transaction covered substantially all assets, including ingestible and wearable technology. Earlier reporting put funding near $500 million and a former valuation at $1.5 billion. Those are approximate company financing and equity measures; the bankruptcy asset price does not establish an exact investor loss or recovery.[7][2][17]
The technology survived the independent company’s failure. FDA and Otsuka still host January 2025 labeling. Otsuka’s current US product list, however, does not list MyCite, and its former consumer site failed retrieval. Those observations do not settle current dispensing availability. Neither a surviving label nor an absent product listing proves a complete product-retirement date.[4][18]
Key Lessons
- Define the benefit separately from the measurement. Recording ingestion creates information. Improving adherence or health requires additional evidence.
- Test the whole care workflow. Patients must use the patch and phone, while clinicians need time and a clear reason to review the resulting data.
- Keep partner payments classified. Equity, development payments, royalties and component purchases fund different parts of a business.
- Evaluate each population on its own evidence. A positive pilot in diabetes and hypertension cannot establish benefit in serious mental illness.
Sources
- FDA approval announcement
- Otsuka asset purchase closing
- Frias J, Virdi N, Raja P, Kim Y, Savage G, Osterberg L. Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial. Journal of Medical Internet Research. 2017;19(7):e246. DOI: 10.2196/jmir.7833. Figure 1 reproduced unchanged. © Juan Frias, Naunihal Virdi, Praveen Raja, Yoona Kim, George Savage and Lars Osterberg, 2017. First published July 11, 2017, in the Journal of Medical Internet Research. Distributed under the Creative Commons Attribution 4.0 International license, which permits reuse with attribution.
- FDA January 2025 prescribing information
- Founder account of product origins
- University of Illinois founding record
- Court-approved cash bid and shareholder objections
- Andrew Thompson direct interview
- Magellan selective rollout
- Expanded Otsuka collaboration
- Contemporary financing and trial difficulties
- Relationship restructuring and oncology pivot
- Drug-device approval and system components
- Digital oncology program announcement
- ASCO gastrointestinal oncology abstract 76
- European application withdrawal
- Reported financing and bankruptcy-sale recap
- Otsuka current US product list
- Apple current medication features
- Medisafe current pricing outside the US
- Medisafe US app listing